MedPath

Prospective cross-over study on the interaction between furosemide and sevelamer in hemodialysis patients.

Completed
Conditions
10038430
dialyse patienten
terminal renal failure
Registration Number
NL-OMON33060
Lead Sponsor
Canisius Wilhelmina Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
6
Inclusion Criteria

age 18-90 years
end stage renal disease, hemodialysis since >=3 months
diuresis> 100ml/d with furosemide
furosemide dosage >=500mg a day
patient can collect 24h urine

Exclusion Criteria

sevelamer is contraindicated
already using sevelamer
cardiovascular instability
clinically overhydrated
engaged in medication research within 1 month prior to inclusion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>volume 24 hr urine<br /><br>Concentration furosemide urine.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>x</p><br>
© Copyright 2025. All Rights Reserved by MedPath